Uncategorized

GC Biopharma, a South Korean biopharmaceutical company, announced on December 6th that it has participated in the groundbreaking ceremony of a plasma fractionation plant held at Jababeka Industrial Estate in Indonesia, one of the company’s overseas plant construction projects.

Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.

EyePoint Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17.00 per share.

Arvinas, Inc. announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc. to discuss vepdegestrant data presented at the 2023 San Antonio Breast Cancer Symposium as well as plans to expand the vepdegestrant development program.

The pharma industry serves patients best when data is shared, and privacy concerns can stand in the way of resolving critical supply chain issues.

Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1.

Fueled partly by increasing lifespans and cancer incidence, the area’s worth is projected to soar to 13.67 billion by 2032, Precedence Research reports.

Under the new model, CVS’ pharmacy network will price drugs based on the amount the company paid for them, plus a defined markup and additional pharmacist fee.

The interim final rule, which is set to go into effect Wednesday, comes as nearly 11.8 million people have been removed from the safety-net insurance.

The company shared “reinforced guidance” to mitigate the risk of underdosing and interruptions to treatment.